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Objective: To report the initial results of a prospective
study aimed at evaluating the CT perfusion parameter
changes (ΔPCTp) of the primary tumour after radio-
chemotherapy (RCT) in head and neck cancer (HNC) and
to correlate with positron emission tomography (PET)/
CT response.
Methods: Eligibility criteria included HNC (Stage III–IV)
candidates for RCT. Patients underwent perfusion CT
(PCT) at baseline and at 3 weeks and 3 months after
treatment. Blood volume, blood flow, mean transit time
(MTT) and permeability surface (PS) product were
computed. Moreover, PET/CT was performed at baseline
and 3 months after treatment. The ΔPCTp were evaluated
between baseline and 3-week/3-month evaluations,
whereas PET/CT response was based on the maximum
standardized uptake value changes according to the
European Organization for Research and Treatment of
Cancer criteria.
Results: Between July 2012 and July 2015, 25 patients
were enrolled. A significant reduction of all CT tumour
perfusion parameters (PCTp) was observed from the
baseline to after RCT (p,0.001). Specifically, a significant
reduction was shown at 3 weeks for all PCTp except MTT
(from 6.18 to 5.14s; p50.722). Differently, a significant
reduction of all PCTp (p,0.001) including MTT (from 6.18
to 2.24s; p50.001) was shown at 3 months. Moreover, the
reduction of PS resulted in a significant prediction of
PET/CT response at 3 months (p50.037) with the trend
also at 3 weeks (p50.099) at the multivariate analysis.
Conclusion: Our preliminary findings seem to show that
almost all PCTp are significantly reduced after RCT,
whereas PS seems to come out as the strongest factor
in predicting the PET/CT response.
Advances in knowledge: This article provides information
on the potential useful role of PCT in evaluating tumour
response after both early and late RCT.
INTRODUCTION
In Western countries, head and neck cancer (HNC) account
for about 5% of all tumours.1,2 Squamous cell carcinoma is
the most common histotype (about 90%) and it generally
arises from the mucosa of the upper aerodigestive tract.
The aetiology of these tumours has traditionally been re-
lated to tobacco and alcohol consumption, whereas in the
past decade, infection from the human papilloma virus
(HPV) has been identified as an emerging cause; most of
the HPV-related HNCs arise in the oropharynx subsite and
they generally carry a better prognosis than the non-HPV-
related cancers.3
HNCs constitute a heterogeneous clinical setting including
five main different subtypes according to the site of the
primary tumour: the nasopharynx, oropharynx, oral cavity,
hypopharynx and larynx. Nevertheless, they are all char-
acterized by a predominant route of locoregional metas-
tasis through the lymphatic route and by a relatively low
proportion of distant haematogenous metastasis.
Therefore, prognosis and therapeutic options are strongly
related to both the subsite of origin and the clinical stage
at diagnosis; these features heavily affect the probability
of control for both the primary tumour and lymph
node disease.
In the past few decades, owing to technological improvements in
treatment delivery and setup control systems such as intensity-
modulated radiotherapy and image-guided radiotherapy, radi-
ochemotherapy (RCT) has emerged as a valid alternative to
radical surgery, resulting in similar rates of local control.4 As
a consequence, interest is rising on new imaging technologies
with the potential of properly evaluating tumour response after
treatment in order to select, as soon as possible during treat-
ment, patients who are “non-responders” who could benefit
from salvage surgery.5
In the current clinical practice, evaluation of tumour response is
based on fibreoptic endoscopy of the head and neck (HN) re-
gion, combined with “morphological” CT-/MR-based imaging.
However, CT and MRI are often inadequate to discriminate
between post-actinic tissue changes and persistence of tumour
[i.e. in the presence of post-radiotherapy (RT) scarring areas]
and often require confirmation by biopsy.6
By adding functional metabolic information to standard radio-
logical imaging, fluorine-18 fludeoxyglucose (18F-FDG)-
positron emission tomography (PET)/CT has emerged in the
past few years as an important advancement for assessing tu-
mour response to treatment, based on its excellent negative-
predictive value (95.1%).
The main drawback of this imaging approach is the non-
negligible rate of early false-positive results (resulting in a 58.6%
positive-predictive value), owing to local enhanced glucose
consumption induced by post-actinic inflammation, although
a high reliability of 18F-FDG-PET/CT has been reported within
10–12 weeks after the completion of RT.7
Nevertheless, efforts are continuing to exploit the full potential
of molecular imaging to both improve the prediction of tumour
response and shorten the timing of the imaging procedure for
therapy response evaluation relative to treatment.8
More recently, obtaining quantitative perfusion CT (PCT) in-
formation on the status of tumour microcirculation that might
reflect early treatment response or predict outcome has been
proposed as a potential additional tool for the non-invasive
functional assessment of treatment response.9–14 Although no
consensus has been reached so far about the optimal timing of
PCT imaging for the assessment of early treatment response,
several experimental studies on both humans and animal
models have shown the ability of PCT to detect changes of PCT
parameters less than 1 month after or even within days of be-
ginning of therapy (i.e. well before a reduction in tumour size
can be demonstrated on conventional morphological CT
imaging).15–17
In this study, we prospectively evaluated the changes in
perfusion parameters (ΔPCTp) of the primary tumour,
measured both at 3 weeks and 3 months after RCT, com-
pared with pre-treatment values. The ΔPCTp values so
obtained were correlated to the changes in 18F-FDG uptake
in the primary tumour measured 3 months after RCT vs the
pre-treatment values.
METHODS AND MATERIALS
This study was carried out as a collaboration involving the divi-
sions of Radiation Oncology, Diagnostic Radiology and Nuclear
Medicine and was conducted according to the Declaration of
Helsinki. All patients gave their written consent to all diagnostic
and therapeutic procedures.
Study design
All patients affected by intermediate or advanced HNC (Stage III
or IV) who were candidates for RCT with curative intent were
enrolled in this study. The eligibility criteria were:
• histologically proven undifferentiated nasopharyngeal-type
carcinoma or squamous cell carcinoma
• tumour arising from one of the following subsites: the
nasopharynx, oropharynx, oral cavity, larynx and
hypopharynx
• no contraindication to concurrent chemotherapy
• absent distant metastases
• no prior induction chemotherapy or HN oncologic treatment
(surgery and/or RT)
• no contraindication to iodinated medium contrast
administration
• absence of metal dental implants possibly affecting the quality
of the CT image.
All patients underwent a complete pre-treatment diagnostic and
staging work-up including panendoscopy of the HN region
with biopsy of the primary tumour, contrast-enhanced CT
(including a perfusion study of the primary tumour as described
in more detail in the dedicated subsection) and 18F-FDG-PET/
CT of the total body.
Contrast-enhanced MR was performed in all patients with na-
sopharynx cancer (to evaluate a possible invasion of the skull
base) as well as in the patients with tumours located at other
sites, when deemed necessary.
PCT was repeated both at 3 weeks and 3 months after the
completion of RCT, in order to evaluate changes in the CT
tumour perfusion parameters (PCTp) values with respect to the
pre-treatment values.
18F-FDG-PET/CT was also repeated 3 months after the com-
pletion of RCT to evaluate the metabolic response of the tumour
to treatment.18,19
Thereafter, routine follow-up was performed according to our
internal protocol based on the current international guidelines.20
Treatment
All RT treatments were performed using an intensity-modulated
radiotherapy technique with a simultaneous integrated boost.
The clinical target volumes were directly delineated by the
radiation oncologist according to the guidelines of the Italian
Association of Radiation Oncology—Head and Neck Working
Group, and the corresponding planning target volumes
(PTVs) were automatically created by uniform expansions
of 0.3 cm.21
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The prescribed doses were 66Gy at 2.2Gy per fraction to the high-
risk gross PTV and 60–54Gy at 2.0–1.8Gy per fraction to the
intermediate (optional) and low-risk subclinical PTVs, respectively,
delivered concomitantly in 30 daily fractions (5 days a week).
According to our internal image-guided radiotherapy protocol,
the patients underwent weekly cone-beam CT setup control and
online correction to reduce the systematic setup errors.
Chemotherapy was given weekly using cisplatin 40-mgm22 i.v.
over 1 h during the 6-week RT course for a maximum of six
cycles or cisplatin 100-mgm22 i.v. once every 3 weeks for
a maximum of three cycles.
Perfusion CT protocol
All PCTstudies were carried out using a high-definition 64-row CT
scanner (Discovery CT750 HD®; General Electric, Milwaukee, WI)
operating in axial mode with a toggling table technique, resulting in
a z-axis coverage of 8 cm (i.e. 23 64 detector rows3 0.625mm
detector collimation, obtained by shifting the CT table back and
forth between two different positions located 4 cm apart from each
other) centred on the lesion site. The scan volume was defined
upon revision of previously acquired morphological CT or MR
images, as identified on a preliminary low-dose contrast-
unenhanced CT scan [axial shuttle mode, detector configuration
643 0.625mm, 100 kV, 20mA, tube rotation time 0.7 s, 2.5-mm
slice thickness, standard convolution kernel and 60% iterative re-
construction strength (ASIR, General Electric, Milwaukee, WI)].
A continuous series of 17 PCT frames was acquired starting 8 s
after the beginning of contrast medium injection for a total ac-
quisition time of 46.6 s, so as to cover the entire duration of the
first pass of contrast medium through the lesion under in-
vestigation. Subsequently, two additional late frames with an
interscan delay of 15 s after the end of the first pass scan to obtain
data over the recirculation phase of the contrast medium for the
computation of the permeability surface (PS) product parameter.
Scanning parameters for all aforementioned PCT scans were the
following: tube voltage 80 kV, tube current 300mA, tube rotation
time 0.4 s, slice thickness 2.5mm, soft convolution kernel and
50% adaptive statistical iterative reconstruction.
The temporal resolution for the axial shuttle PCT protocol
was 2.8 s.22
For all PCT examinations, 50ml of iodixanol 320mgI/ml (Vis-
ipaque 320®, GE Healthcare, Oslo, Norway) was injected in-
travenously at a flow rate of 4ml s21 using a power injector
(Medrad Stellant®, Bayer Healthcare, Leverkusen, Germany) via
a 20-G needle positioned in the antecubital vein, followed by
50ml of saline flush administered at the same flow rate.
The mean dose–length product for the whole CT examination
was 4456 13mGy cm, corresponding to an effective dose of
1.386 0.04mSv (k5 0.0031mSvmGy21 cm21)23
Post-processing of CT perfusion data
All PCT data sets were transferred via local area network to
a workstation (Advantage Windows v. 4.5; General Electric,
Milwaukee, WI) equipped with a dedicated plug-in (CT Perfu-
sion 3 plugin) for the computation of the following CT perfu-
sion parameters.
Blood flow
The blood flow (BF) transiting from the arterial input through
the tissue intravascular space is expressed as millilitres per
minute per 100 g of tissue. BF provides information on BF from
large vessels, arterioles, capillaries and venules as well as arter-
ovenous shunts, which are typical of tumour neoangiogenesis
(leading to an increase of tumour BF compared with the nor-
mal tissue).
Blood volume
The blood volume (BV) that passes through the intravascular
space is expressed as millilitres per 100 g of tissue. Along with
BF, it is typically increased in tumour neoangiogenesis as a result
of an enlarged neovascular bed.
Mean transit time
The mean transit time (MTT) is the mean time required for the
blood to travel from the arterial input to the venous end,
expressed in seconds. It can be expressed as the ratio between
BV and BF (central volume theorem) and tends to be reduced in
tumours with neoangiogenesis owing to increased perfusion
pressure and the presence of arterovenous shunts.
Permeability surface product
The product between permeability and the total surface area of
the capillary endothelium in a unit mass of tissue, expressed as
millilitres per minute per 100 g of tissue. This parameter is
considered as a surrogate marker of neoplastic neoangiogenesis
and represents the rate of efflux of contrast medium from the
intravascular space to the interstitial space during its in-
travascular distribution phase, which is directly related to vas-
cular permeability.24
Circular regions of interest (ROIs) were positioned inside the
lesion, as well as on the ipsilateral common or external carotid
artery, for sampling of the arterial input function needed to
compute the CT perfusion parameters. As the tumour tissue was
visible on multiple slices in all cases, ROIs were placed on the
slice containing the largest tumour section in order to maximize
the amount of sampled data per patient. ROI contours were kept
at a distance of at least 1mm from the tumour border to avoid
partial volume effect and care was taken to avoid macroscopic
areas of tumour necrosis or calcification.25
All ROIs were identified with a blind system by two radiologists
with 10 and 3 years’ experience in HN imaging and by a radia-
tion therapist with 9 years’ experience. Each PCT parameter
considered for this analysis is the average of the three meas-
urements by the three readers.
Positron emission tomography/CT protocol
PET/CT scans were acquired using a Discovery 710 PET/CT
scanner (GE Healthcare, Milwaukee, WI). The scanner employs
13,824 lutetium yttrium orthosilicate (LYSO) crystals in 24 de-
tector rings to provide 47 slices per bed position. The spatial
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resolution is approximately 5-mm full width at half maximum.
The system is able to record “time of flight” information be-
tween two events in coincidence. Each patient underwent PET/
CT acquisition at least 60min after 18F-FDG injection, following
good hydration. All the patients had fasted for at least 6 h and at
the time of 18F-FDG administration, blood glucose levels were
below 150mg dl21. Injected activity was 3.7MBq/kg. Emission
imaging was performed in three-dimensional mode with an
acquisition time of 2–3min per bed position (neck–pelvis) with
5–6 bed positions per patient.
The CT acquisition protocol included low-dose CT for anatomic
localization (64 slices, 80mAs, 120 kV, 0.5 s per rotation and
3.75-mm slice thickness) from the skull to mid-thigh, with the
arms down.
Image reconstruction
The emission data were corrected for random events, dead time,
scatter and attenuation. A three-dimensional ordered-subsets
expectation maximization iterative reconstruction algorithm was
applied with 3 iterations and 21 subsets, with Gaussian smoothing
of 4mm in full width at half maximum, in a 5163 516 matrix
and a 60-cm field of view. Attenuation maps were obtained from
the low-dose CT data by bilinear transformation, as implemented
in the post-processing software of the PET/CT scanner, and were
used for attenuation correction of the PET data.
All images were uploaded onto a dedicated workstation (Advantage
Workstation, 4.4; GE Healthcare, Milwaukee, WI). A nuclear med-
icine physician analyzed the images visually and semi-quantitatively
using the standardized uptake value (SUV) of 18F-FDG [maximum
standardized uptake value (SUVmax) corrected for body weight];
to calculate SUVs of the suspected tumour lesions, the axial slice
with the maximum SUV of the lesion was first identified.
According to the European Organization for Research and Treat-
ment of Cancer (EORTC) criteria,26 evaluation of metabolic re-
sponse to treatment was based on the changes in SUVmax as follows:
• Complete response (CR): no uptake in the tumour or
18F-FDG uptake similar to that in the mediastinum
• Partial response (PR): .25% decrease in SUVmax of the
tumour as defined on the pre-treatment scan with no disease
progression at other sites
• Stable disease (SD): ,25% increase or ,15% decrease in
SUVmax of the tumour as defined on the pre-treatment scan
and no new sites of disease
• Progression of disease (PD): .25% increase in SUVmax of the
tumour as defined on the pre-treatment scan or appearance of
new 18F-FDG uptake in metastatic lesions.
Based on the above criteria, patients were divided into complete
responders (patients with CR), partial responders (patients with
PR) and non-responders (patients with SD or PD).
Statistical analysis
Before applying the inferential tests, a descriptive analysis of the
quantitative variables (BF, BV, MTT and PS) was performed and
the PCTp values were tested with the Kolmogorov–Smirnov
normality test.
Assessment of CT tumour perfusion parameters
To assess the treatment-related differences of the PCTp values,
a repeated measures general linear model (GLM) was adopted,
followed by multiple comparisons with Bonferroni’s method.
Eight new variables, two for each PCTp, were calculated as the
difference between the baseline and the 3-week and the 3-month
values, respectively.
Evaluation of predictive factors of positron emission
tomography/CT response
The variable “PET/CT response” (expression of the metabolic
response to treatment) was included in the statistical analysis
and considered as 0 for CR, 1 for PR and 2 for SD1PD.
The evaluation of PET/CT score prognostic factors (differences
of the PCTp at 3 weeks and 3 months after treatment) was
performed by a “scale response” univariate GLM. Subsequently,
all the significant variables were included in a “scale response”
multivariate GLM to determine the contribution of each prog-
nostic factor to the PET/CT score.
The results of the multivariate predictive model were expressed
by the p-values and regression coefficients. Finally, to ensure
correctness of the prediction model, a histogram-based residual
analysis was performed. The significance was set at 0.05.
All statistical analyses were carried out using SPSS technology
v. 22 (IBM Corporation, Armonk, NY).
RESULTS
Patient and tumour characteristics
Between July 2012 and July 2015, 27 patients with in-
termediate and locally advanced HNC who were candidates
for RCT were screened for possible enrolment in the study.
Two of these patients were excluded because the pre-treatment
18F-FDG-PET/CT disclosed the presence of hepatic metastases
in one case and a synchronous primary colon tumour in the
other case.
Overall, 25 patients were definitively enrolled in the study;
19 patients were affected by intermediate or locally advanced
HNC and 6 by nasopharyngeal cancer (4 World Health
Organization III and 2 World Health Organization II).
All enrolled patients completed the planned treatment and im-
aging procedure protocols and were therefore evaluable for the
final analysis; all data sets were of sufficient quality with no or
negligible artefacts due to patient motion.
Baseline patient and tumour characteristics are summarized
in Table 1.
Overall, according to 18F-FDG-PET/CT parameters of tumour
response, CR was found in 16/25 (64%) patients, PR in 7/25
(28%) patients, SD in 1/25 (4%) patients and PD in 1/25 (4%)
patients. Moreover, according to the standard radiological re-
sponse evaluation criteria in solid tumour (RECIST), 17/25
(68%) patients exhibited CR while the remaining 8 (32%)
patients exhibited PR.
BJR Ursino et al
4 of 10 birpublications.org/bjr Br J Radiol;89:20151070
Variations of tumour perfusion parameters
The primary analysis was aimed at assessing the variations of
each tumour perfusion parameter in the post-treatment PCT
(both at 3 weeks and 3 months) with respect to the pre-
treatment values.
The mean and range values of each tumour perfusion parameter
(BV, BF, MTT and PS) at different times together with the sig-
nificant p-values corresponding to the variations observed at
each time point (baseline, then 3 weeks and 3 months after
treatment) are reported in Tables 2 and 3.
Overall, a significant reduction of all PCTp in the post-RCT
scan was observed with respect to the baseline PCT. In
particular, a significant reduction of all the PCTp values
except MTT was observed in the 3-week post-RCT PCT with
respect to baseline. Instead, all PCTp values, including MTT,
were significantly lower than the baseline values in the
3-month PCT.
As for the differences in PCTp values between the 3-week and
3-month PCT post-RCT, MTT was the only parameter with
a significant reduction (p5 0.036), while the differences were at
borderline of statistical significance for BV (p5 0.066) and for
BF (p5 0.061).
Relationship between positron emission
tomography/CT response and DPCTp
A secondary analysis was aimed at assessing the relationship
between the PET/CT response and DPCTp both at 3 weeks and
3 months post-treatment. The results of univariate and multi-
variate analyses are reported in Table 4.
The PET/CT response resulted to be significantly correlated
to a reduction of all PCTp values both at 3 weeks and at
3 months, except for MTT. Multivariate analysis, which took
into account only the variables found to be significant by
univariate analysis, showed that PS was the only parameter
to maintain a statistical significance at 3 months (p5 0.037),
with a trend towards statistical significance also at
3 weeks (p5 0.099).
DISCUSSION
The primary aim of this study was to investigate changes in the
PCTp of the primary tumour induced by RCT in patients af-
fected by intermediate and locally advanced HNC. The rationale
was based on the objective evaluation of tumour vascularity
changes as a surrogate for the RCT effect.
For this purpose, we focused on the DPCTp both at 3 weeks and
3 months, whereas the post-RCT PET/CT was performed
3 months after treatment, as the standard procedure for
assessing metabolic response of the tumour after RCT.14
The results obtained showed a significant reduction of all
PCTp values, except MTT, already as early as 3 weeks after
treatment, thus demonstrating a strong effect of RCT on
such parameters. Therefore, MTT was the least sensitive
parameter to demonstrate the effect of RCT, as it took longer
(3 months) for its reduction with respect to baseline to reach
statistical significance. On the contrary, BV, BF and PS
resulted to be highly sensitive parameters, as they exhibited
a significant reduction already at 3 weeks post-RCT, with a
trend towards further reduction in the 3-month PCT scan vs the
3-week scan.
Table 1. Patients and tumour characteristics
Characteristics
Number of
patients
%
Risk factors
Smoking status 25
Smokers 16 64
,10 cigarettes/day 4 16
.10 cigarettes/day 12 48
Non-smokers 9 36
Alcohol 25
Potus 7 28
Non-potus 18 72
Site
Nasopharynx 6 24
Oropharynx 7 28
Oral cavity 5 20
Hypopharynx 2 8
Larynx 5 20
Histology
Squamous cell carcinoma 21 84
Undifferentiated carcinoma 4 16
T
2 13 52
3 4 16
4 8 32
N
0 7 28
1 4 16
2 12 48
3 2 8
Stage
III 9 36
IV 16
IVA 11 44
IVB 5 20
Concurrent chemotherapy
Cisplatin 40 mg/mq weekly 24 96
Cisplatin 100 mg/mq
every 21 days
1 4
Potus, chronic alcohol consumption .1 l/day
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In this regard, the radiation- and chemotherapy-induced dam-
age on the intratumour microvasculature and low-resistance
flow of neoplastic vessels explain the reduction induced by RCT
in the BV and BF values, whereas the observed decline in the PS
values might be explained by reduced neoangiogenesis.
Despite the relatively small sample size (25 patients), these
results are promising as to the potential role of PCT to predict
tumour response, consistent with the few prior reports pub-
lished to date. In particular, Gandhi et al27 studied nine patients
and found a linear relationship between high baseline BV values
and tumour response after neoadjuvant chemotherapy. In
a study including 25 patients, Petralia et al28 reported similar
results, showing a significant reduction of both BV and BF after
3 cycles of induction chemotherapy. Similarly, Truong et al29
observed a positive correlation between high baseline BF values
and longer locoregional control, consistent with the findings
reported by Hermans et al.30 Finally, Surlan-Popovic et al31 in-
vestigated the changes of tumour perfusion parameters during
the course of RT and observed a significant reduction of BV and
BF, whereas MTT and PS did not change significantly.
Although the few reports published so far on this subject include
relatively small groups of patients, the overall findings consistently
suggest a predictive role of high pre-treatment BV and BF values as
well as reduction in the perfusion parameters induced by radiation
and/or chemotherapy. Differently, most of the earlier studies report
contradictory findings regarding the changes in PS and MTT
values induced by treatment, with no significant variations in
the post-treatment vs pre-treatment values found in most
reports.32 It should also be noted that MTT seems to have
a pivotal role in the interpretation of tumour response to
treatment. In particular, Petralia et al28 reported a significant
increase in the MTT values induced by treatment, a finding
that the authors interpret as due to the reduction of the
amount of arterovenous neoplastic shunts, combined with
reduction of the BV and BF values.
In contrast with the above findings, our results showed a sig-
nificant reduction of all perfusion parameters, including the
MTT value at 3 months after treatment. A possible explanation
of our findings might be the high rate (68%) of CR based on the
standard RECIST that precluded a real computation of MTT
value, therefore assigning a zero value to this variable for sta-
tistical analysis. Indeed, the patients with PR to treatment
exhibited an overall increase (although not statistically signifi-
cant) of the MTT values (from a baseline mean value of 6.1 s to
a mean value of 7.0 s 3 months after RCT), thus confirming the
findings reported by Petralia et al.28
Therefore, there is increasing interest in investigating the po-
tential role of morphological–functional integrated imaging
technique in the interpretation of tumour response after RCT,
mostly focusing on early evaluation.
Table 2. Tumour perfusion parameter variation scores from baseline to post-treatment
Timing BV (ml/100 gmin21) BF (ml/100 g) MTT (s) PS (ml/100 gmin21)
Baseline
Mean 32.53 396.76 6.18 47.63
Range 5.48–84.66 76.67–880.62 2.16–11.21 4.41–98.80
3 weeks
Mean 13.42 192.12 5.14 24.07
Range 0–52.61 0–679.61 0–11.96 0–74.75
3 months
Mean 5.67 74.26 2.24 11.58
Range 0-48.97 0–536.77 0–18.94 0–92.81
BF, blood flow; BV, blood volume; MTT, mean transit time; PS, permeability surface.
Table 3. Statistical significance of tumour perfusion parameter variations
Comparison of DPCTp at different times
p-value
BV BF MTT PS
Repeated measures ,0.0001 ,0.0001 0.001 ,0.0001
Multiple comparison
Baseline vs 3 weeks 0.001 0.002 0.722 0.004
Baseline vs 3 months ,0.0001 ,0.0001 0.001 ,0.0001
3 weeks vs 3 months 0.066 0.061 0.036 0.089
BF, blood flow; BV, blood volume; MTT, mean transit time; PS, permeability surface.
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In fact, though a real benefit of early vs delayed surgery in
prescence of gross residual tumour mass after RCT has not been
proved yet, it is likely to be.
As a consequence, a precocious identification of patients who
were partial or non-responders might be really useful in
clinical practice (probably for primary tumour more than for
adenopathy) to drive them to a salvage surgery as soon as
possible in order to improve oncologic outcomes.
As a secondary goal of the study, the findings regarding changes
in the PCTp values induced by RCT and correlated with the
PET/CT tumour response at 3 months were considered by most
authors to constitute the standard of care for metabolic assess-
ment in clinical practice.33 Based on the EORTC criteria, the
metabolic response was classified into CR, PR, SD and PD; for
statistical analysis, PET/CT response was considered as a di-
chotomous variable (CR vs PR, SD and PD).
Interestingly, PS values at 3 months post-RCTwere the strongest
predictors of subsequent PET/CT response. As a matter of fact,
the PS reduction at 3 months maintained statistical significance
at multivariate analysis (p5 0.037), with a trend towards sta-
tistical significance (p5 0.099) also for the reduction at 3 weeks.
Therefore, among all PCT parameters, PS emerges as the
strongest predictor of metabolic tumour response to treatment.
Based on the few previous reported experiences, a possible
pathophysiological explanation of our findings might be an
uppermost effect of RCT on tumour neovascularization, with
consequent early reduction of endothelium vascular perme-
ability together with BV and BF associated with possible un-
changed or slightly increased values of mean blood transit time.
Subsequently, a delayed reduction of MTT consequent to the
tumour neovasculature radiation-induced disruption together
with a further significant decrease of all the other perfusion
parameters could occur later.
Table 4. Univariate and multivariate analyses of positron
emission tomography/CT response and tumour perfusion
parameter variations
Perfusion
parameter
changes
Univariate
analysis
Multivariate
analysis
p-value RC p-value
PCTp baseline—3 weeks
BV 0.030 20.001 0.923
BF 0.042 20.0003 0.800
MTT 0.998 — —
PS 0.014 20.010 0.099
PCTp baseline—3 months
BV 0.038 0.009 0.446
BF 0.032 20.001 0.472
MTT 0.692 — —
PS 0.005 20.013 0.037
BF, blood flow; BV, blood volume; MTT, mean transit time; PCTp, CT
tumour perfusion parameters; PS, permeability surface; RC, regression
coefficient.
Figure 1. Early radiologic response assessment in a 75-year-old patient with squamous cell carcinoma of the oral tongue treated with
radiochemotherapy (RCT): (a) pre-treatment morphologic CT image obtained from first-pass perfusion CT (PCT) data set. (b)
Blood volume (BV), (c) blood flow (BF), (d) mean transit time (MTT) and (e) permeability surface (PS) colour maps are showing
altered lesion perfusion compared with the surrounding tongue tissues. (f) Post-treatment morphologic CT image obtained from
first-pass PCT data set. Quantitative measurement of pre-treatment PCT parameters revealed BV53.40mlmin21, BF584mlmin21
per 100g, MTT52.74 s and PS5 12.3mlmin21 per 100g, respectively. (g) BV, (h) BF, (i) MTT and (j) PS colour maps are showing
normalization of lesion perfusion 3 weeks after RCT treatment. Quantitative measurement of post-treatment PCT parameters
revealed BV52.03mlmin21, BF534mlmin21 per 100g, MTT56.74 s and PS59.25mlmin21 per 100g, respectively.
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Figures 1 and 2 report the imaging findings in a case that briefly
symbolizes our results. This patient was affected by a locally
advanced oral cavity tumour (Stage cT4aN1) and exhibited early
radiologic PR (.50% reduction based on RECIST) combined
with a significant early reduction of all PCTp but MTT at
3 weeks (Figure 1) and with a subsequent complete metabolic
response 6 months after RCT (Figure 2).
These results, obtained in a relatively small sample size and with
a short follow-up, require further independent confirmation in
other series.
Anyway, a similar experience was recently published by Pietsch
et al34 on 13 patients with HNC treated with RCT who had un-
dergone PCT and PET/CT both at baseline and after treatment.
The authors found a significant correlation between high base-
line values of BV, BF and tumour lesion glycolysis and tumour
recurrence, whereas no statistically significant correlation be-
tween DPCTp and DPET/CTp was observed.
Interestingly, owing to the short study protocol (as stated by the
authors themselves), the PS product was the only parameter not
calculated; so, our preliminary findings might suggest a possible,
not previously reported, prognostic role of PS.
Anyway, the correlation of DPCTp with PET/CT response based
on EORTC criteria was a major limitation of our experience, as
SUVmax changes are not really an appropriate oncological end
point and its clinical value is limited.
Thus, longer follow-up and greater sample size are warranted
to correlate tumour perfusion parameter changes to more
important clinical outcomes, such as local recurrence-free
survival and/or cancer-specific survival in order to properly
evaluate the prognostic role of PCT in tumour response
evaluation.
Our findings are still preliminary in nature and future larger
prospective studies, with a longer follow-up, are needed to
confirm their validity.
In the meantime, we suggest always taking into account the
functional and morphological data of PCT imaging, mostly in
the presence of positive cases, in order to reduce the rate of false
positivity as much as possible.
Figure 2. Metabolic fluorine-18 fludeoxyglucose (18F-FDG)-positron emission tomography (PET) response assessment in the same
patient as in Figure 1 6 months after radiochemotherapy (RCT). (b) Pre-treatment axial 18F-FDG-PET and (c) PET/CT fused images
are showing a focal abnormal tracer uptake in the tongue. (e) 18F-FDG-PET and (f) PET/CT performed 6 months after RCT are
showing the absence of focal uptake in the tongue after complete metabolic response to treatment.
BJR Ursino et al
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